Tag: biotech

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Stem Cell Culture Media Market size & share revenue was valued at approximately USD 765 Million in 2025 and is expected to reach USD 868 Million in 2026 and is expected to reach around USD 2714 Million by 2035, at a CAGR of 13.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are PAN Biotech GmbH, Sartorius AG, Cytiva, Lonza Group AG, Corning Incorporated, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG, PromoCell GmbH, Biological Industries Ltd., CellGenix GmbH, Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merck KGaA and others.